For the quarter ending 2025-11-30, BMRA had -$510K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-11-30 | 2025-08-31 | 2025-05-31 |
|---|---|---|---|
| Net loss | -1,320 | 2 | -4,973 |
| Depreciation and amortization | 20 | 20 | 87 |
| Provision for allowance for credit losses | 32 | 38 | 8 |
| Inventory reserve | -44 | 7 | 4 |
| Share-based compensation | 117 | 133 | 460 |
| Amortization of right-of-use asset | 83 | 82 | 313 |
| Accounts receivable | -227 | 512 | -209 |
| Inventories | 8 | -10 | -882 |
| Prepaid expenses and other | 9 | -87 | 17 |
| Other assets | -11 | -5 | -8 |
| Accounts payable and accrued expenses | 60 | 10 | -466 |
| Accrued compensation | -47 | -63 | 1 |
| Advances from customers | -24 | -1 | -30 |
| Reduction in lease liabilities | -89 | -86 | -327 |
| Net cash used in operating activities | -991 | -268 | -3,841 |
| Purchases of property and equipment | - | - | 0 |
| Expenditures related to intangibles | - | - | 37 |
| Net cash used in investing activities | - | - | -37 |
| Gross proceeds from sale of common stock | 493 | 939 | 2,143 |
| Deferred offering costs | - | - | 3 |
| Costs from sale of common stock | 11 | 19 | 44 |
| Proceeds from exercise of stock options | - | - | 15 |
| Net cash provided by financing activities | 482 | 920 | 2,111 |
| Effect of exchange rate changes on cash | -1 | 2 | -3 |
| Net increase (decrease) in cash and cash equivalents | -510 | 654 | -1,770 |
| Cash and cash equivalents at beginning of period | 3,053 | 2,399 | - |
| Cash and cash equivalents at end of period | 2,543 | 3,053 | - |
BIOMERICA INC (BMRA)
BIOMERICA INC (BMRA)